Health
Merck discontinues a crucial antibiotic amid concerns about superbug resistance.
Publication: STAT
Author: Ed Silverman
Source published: 28/09/2026, 20:45:43 UTC
Briefing created: 28/09/2026, 20:53:56 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 28/09/2026, 20:51:24 UTC.
Briefings
Merck abruptly discontinued the Recarbrio antibiotic from the U.S. market in September 2026, a move driven by concerns over superbug resistance despite the drug being FDA-approved as a last-resort treatment for severe infections like pneumonia and urinary tract issues. The company did not explain the decision, and sales figures were not disclosed in regulatory filings, limiting public understanding of the impact on market potential.
Key points
- Merck discontinued the Recarbrio antibiotic from the U.S. market in September 2026 due to concerns about superbug resistance, even though the drug was FDA-approved as a last-resort treatment for severe infections like pneumonia and urinary tract issues.
- The company did not disclose specific sales figures for Recarbrio in its regulatory filings, limiting public understanding of the impact on market potential.
Context and limitations
The evidence is limited to a single article from September 2026; specific reasons for discontinuation, future sales projections, and long-term market impact remain unknown.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 28/09/2026, 20:53:56 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeigvx5lsgvawxe3hophdqlagtyqepptilicyfmhctpw3ebhvjawlyu